Uricase from Candida sp.

SIGMA/U0880 - recombinant, expressed in E. coli, lyophilized powder, ≥2 units/mg solid

Synonym: Urate: oxygen oxoreductase

CAS Number: 9002-12-4
MDL Number: MFCD00082126
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-U0880-250UN	250 units	$172.00 1/EA	Add To Favorites
45-U0880-1000UN	1000 units	$511.00 1/EA	Add To Favorites

This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: U0880-1000UN

Properties
Descriptions
Safety Info.
Basic Data

form	lyophilized powder
InChI	1S/C18H23N4O14P.H3N/c23-5-7-14(13(28)16(34-7)22-4-2-10(25)20-18(22)30)36-37(31,32)33-6-8-11(26)12(27)15(35-8)21-3-1-9(24)19-17(21)29;/h1-4,7-8,11-16,23,26-28H,5-6H2,(H,31,32)(H,19,24,29)(H,20,25,30);1H3
InChI key	VPXDHZMLJOJKOX-UHFFFAOYSA-N
mol wt	35 kDa by SDS-PAGE
Quality Level	200
recombinant	expressed in E. coli
SMILES string	[P](=O)([O-])(OC3C(OC(C3O)N4C=CC(=O)NC4=O)CO)OCC1OC(C(C1O)O)N2C=CC(=O)NC2=O.[N+H4]
specific activity	≥2 units/mg solid
storage temp.	−20°C

Application:	Uricase from Candida sp. has been used: • to eliminate urate in plasma samples and evaluate the contribution of urate to the total plasma antioxidant capacity • to intraperitoneally inject the mice to study the role of uric acid in fibrin extracellular traps (ET) formation • for elimination of uric acid in ferric reducing/antioxidative power (FRAP) assay to measure the total antioxidative capacity of human plasma sample; in uricase-based biosensors
Biochem/physiol Actions:	Uricase participates in purine catabolism. It catalyzes the conversion of highly insoluble uric acid into 5-hydroxyisourate. Accumulation of uric acid causes liver/kidney damage or chronically causes gout. In mice, a mutation in the gene encoding uricase causes a sudden increase in uric acid. Mice, deficient in this gene, exhibit hyperuricemia, hyperuricosuria, and uric acid crystalline obstructive nephropathy.
General description:	Uricase deficient mice develop uric acid nephropathy and diabetes insipidus which can be mitigated with recombinant uricase treatment.
General description:	Uricase is a homo-tetrameric protein with its active sites at the head-to-tail monomer-dimer interface.
Other Notes:	One unit will oxidize 1.0 μmole of uric acid to allantoin per minute at pH 8.5 at 25 °C.
Packaging:	250, 1000 units in glass bottle
Physical form:	Powder; contains citrate and sucrose

RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

activity	specific activity: ≥2 units/mg solid
Storage Temp.	−20°C
Enzyme Commission (EC) Number	1.7.3.3 ( BRENDA \| IUBMB )
UNSPSC	12352204

To Order From a Quote